The Collision of Cardiology’s Past & Future: ACC & EuroPCR 2021

I am certain the new guidelines that we will be seeing soon will also emphasize the importance of coronary CTA.

– Malissa Wood, Massachusetts General Hospital, Session 805 @ ACC.21

The recently completed ACC.21 and EuroPCR 2021 conferences provided an amazing opportunity to understand where cardiovascular care stands today. But beyond that, I was struck that while advances from decades ago still influence us today, there remain significant opportunities for patient-care breakthroughs ahead.

The DISCOVER-FLOW 10-year Outcomes presentation allowed us to revisit the first study ever to assess accuracy and feasibility of a coronary CTA + FFRCT pathway. The original publication from 2011 found FFRCT to be an accurate tool to non-invasively assess lesion-specific physiology in patients with coronary artery disease (CAD). Through remarkable diligence, near universal 10-year follow up was acquired in >100 patients, providing clinicians with high confidence that clinical treatment decisions informed by FFRCT will lead to improved patient outcomes over both the short and long term.

While this 10-year follow-up period is longer than any we have seen before, the finding that the coronary CTA + FFRCT pathway can effectively stratify patient risk is of course not without precedent. During ACC.21, Dr. David Maron (Prof. of Medicine at Stanford University) highlighted that an important and unexpected finding from the ISCHEMIA trial, on which he served as the PI, was that “CCTA can be used to assess prognosis because anatomic burden predicts risk whereas ischemia severity does not.”

He was one of many during the meetings to voice the need to elevate the role of coronary CTA in daily clinical work to identify and diagnose CAD. Over and over, presenters alluded to the fact that US guidelines have not yet embraced coronary CTA as others around the world have:

“[Today’s US approach] is an outdated evaluation strategy. There has been a substantial amount of evidence, particularly with noninvasive anatomic testing, which has been published since 2012, and it’s time for us to redesign and put forth more novel approaches which reflect contemporary evidence.”

Dr. Leslee Shaw, Prof. of Health at Weill Cornell Medicine, ACC Session 677

“Another implication may be a decline in future use of stress testing vs CTA+FFR… The reason for elevating CTA way up in the hierarchy of diagnostic testing [in Europe] is a question about the future use of stress testing: In ISCHEMIA, 14% of patients screened had no obstructive disease and left-main disease was missed in 5.1% of patients, and then picked up on the routine CTA.”

Dr. Bernard Gersh, Prof. of Medicine at Mayo Clinic, ACC Session 805

While this consistent push to apply the lessons from many premier trials regarding coronary CTA + FFRCT for the evaluation and diagnosis of CAD was exciting to see, even more exciting were presentations indicating where this modality can go in the future, as seen in the P3 study.

The Precise PCI Plan (P3) study evaluated the accuracy of the HeartFlow Planner in calculating physiology (FFRCT) after modeling the elimination of coronary narrowings to understand the potential impact of a PCI. Through the ability to non-invasively model different potential treatment strategies, the investigators were able to understand in advance which approaches might allow them to achieve complete functional revascularization, which has been associated with improved clinical outcomes. The P3 study showed that the HeartFlow Planner was “accurate and precise” when using invasive post-PCI physiology as the gold standard, regardless of the pattern of CAD(whether focal or diffuse) or coronary calcification. Principal Investigator Dr. Carlos Collet stated that the HeartFlow Planner “expands the use of CCTA from a diagnostic method to a planning tool for revascularization.”

While there were many other impactful clinical presentations at ACC.21 and EuroPCR, these studies and presentations highlight the constant and healthy tension present when we are forced to assess today’s clinical cardiovascular care in light of where we have been and where we need to go.

The view of the future seen in these data during these conferences is truly exciting. There is an opportunity before each of us to advocate within our own sphere of influence to ensure that the next cardiovascular breakthrough transitions from conference presentation to clinical practice faster than those in the past.

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.